CD133/CD49a discriminate between human pluripotent stem cell-derived pancreatic beta and alpha cells

Area of Science:

• Stem Cell Biology
• Endocrinology
• Cellular Therapeutics

Background:

• Human pluripotent stem cells (hPSCs) offer a renewable source for pancreatic beta cells, crucial for diabetes research and drug discovery.
• Current methods struggle with purity, leading to contamination by off-target and polyhormonal cells, hindering reliable applications.
• Highly purified beta cell populations are essential for accurate disease modeling and effective drug development.

Purpose of the Study:

• To develop and validate a robust cell-sorting strategy for enhancing the purity of stem cell-derived beta (SC-beta) cells.
• To identify reliable surface markers for distinguishing SC-beta cells from other endocrine cell types.
• To improve the utility of hPSC-derived beta cells in preclinical research settings.

Main Methods:

• Utilized cell sorting based on surface marker expression to purify SC-beta cells.
• Identified CD133 (PROM1) as a beta cell-enriched marker and CD49a (ITGA1) as a pan-endocrine marker.
• Validated the purification strategy across multiple hPSC lines and differentiation protocols.

Main Results:

• CD133 combined with CD49a significantly enriched SC-beta cells.
• This dual-marker approach drastically reduced contamination by alpha cells, polyhormonal cells, and ductal cells.
• The purification method demonstrated consistency across different hPSC lines and differentiation protocols.

Conclusions:

• A novel cell-sorting strategy using CD133 and CD49a effectively enhances SC-beta cell purity.
• This improved purity advances the application of hPSC-derived beta cells for disease modeling and drug development.
• The validated method provides a reliable tool for generating high-purity beta cell preparations from stem cells.